The Clinical Protocol, Data Management and Informatics (CPDMI) Shared Resource administrates clinical oncology research at the University of New Mexico (UNM) Cancer Center under the supervision of the Clinical Research Committee. The Medical Director of the CPDMI is D. Jones, who has extensive experience in clinical oncology research, and the Executive Director is T. Stewart. This Shared Resource has a current budget (FY2008/9) of $1.3 million. The CPDMI consists of 1 Medical Director, 1 Executive Director, 1 Regulatory Manager, 1 Quality Assurance Manager, 1 Database Administrator, 4 regulatory coordinators, 2 administrative assistants, 1 human protection specialists, and 1 Program Manager/accountant. The CPDMI includes a clinical informatics effort led by Kroth, which has 4 FTE, and a clinical trials imaging effort led by Eberhardt. The major goal of this Shared Resource is to provide support of the clinical trial process, including implementing and regulating trials, and providing a centralized clinical trial database, investigational pharmacy support, financial accounting, data safety monitoring, and quality assurance. This Shared Resource also assists physician investigators in the design and subsequent conduct of clinical trials. It performs all regulatory reporting and quality assurance needed to comply with Good Clinical Practice in the performance of clinical trials. The CPDMI has created Standardized Operating Procedures for all its activities, including training of all new faculty and staff. In FY2008/9, the CPDMI Shared Resource administrated 327 Cancer Center protocols, of which 114 were therapeutic/interventional trials. These therapeutic trials are also open within the New Mexico Cancer Care Alliance, the consortium of community oncologists affiliated with the UNM Cancer Center. At UNM Cancer Center outpatient clinics, 2640 new cancer patients (Summary 3) were treated in fiscal year 2009, and there were 443 accruals to therapeutic trials (17% of new patients), with an additional 101 therapeutic accruals supervised by the CPDMI at the Alliance affiliate sites. Accruals to all types of trials using the CPDMI were 1241 in fiscal year 2009. Of patients accrued to therapeutic clinical trials, 83% were women, 7% were Native Americans, and 44% were Hispanics. The UNM Cancer Center patient population had 56% women, 11% Native Americans, and 34% Hispanics. Additionally, the CPDMI reviewed 137 subject records as part of internal audits at UNM Cancer Center and affiliate sites.

Public Health Relevance

A major goal of the UNM Cancer Center is to develop new treatments for cancer patients. These new treatments must be tested using clinical research. This Shared Resource is responsible for administrating the clinical trials of the UNM Cancer Center. This administration of the clinical research enterprise implements and regulates clinical trials, and provides a centralized clinical trial database, investigational pharmacy support, financial accounting, data safety monitoring, and quality assurance. These elements are essential for testing new cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA118100-09
Application #
8545088
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
9
Fiscal Year
2013
Total Cost
$148,691
Indirect Cost
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Guo, Yan; Yu, Hui; Wang, Jing et al. (2018) The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. Genes (Basel) 9:
Hatch, Ellen W; Geeze, Mary Beth; Martin, Cheyenne et al. (2018) Variability of PD-L1 expression in mastocytosis. Blood Adv 2:189-199
Frerich, Candace A; Brayer, Kathryn J; Painter, Brandon M et al. (2018) Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes. Oncotarget 9:7341-7358
Kinney, Anita Y; Howell, Rachel; Ruckman, Rachel et al. (2018) Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial. Contemp Clin Trials 73:123-135
Tasnim, Humayra; Fricke, G Matthew; Byrum, Janie R et al. (2018) Quantitative Measurement of Naïve T Cell Association With Dendritic Cells, FRCs, and Blood Vessels in Lymph Nodes. Front Immunol 9:1571
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Castleman, Moriah J; Pokhrel, Srijana; Triplett, Kathleen D et al. (2018) Innate Sex Bias of Staphylococcus aureus Skin Infection Is Driven by ?-Hemolysin. J Immunol 200:657-668
Barton, Matthias; Filardo, Edward J; Lolait, Stephen J et al. (2018) Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. J Steroid Biochem Mol Biol 176:4-15
Prossnitz, Eric R (2018) GPER modulators: Opportunity Nox on the heels of a class Akt. J Steroid Biochem Mol Biol 176:73-81
Perez, Dominique R; Nickl, Christian K; Waller, Anna et al. (2018) High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. SLAS Discov 23:732-741

Showing the most recent 10 out of 344 publications